AREV Life Sciences Global Valuation
Is AREV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AREV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AREV's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AREV's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AREV?
Other financial metrics that can be useful for relative valuation.
What is AREV's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CA$2.86m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 15.7x |
Enterprise Value/EBITDA | -1.8x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AREV's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5x | ||
RTI Radient Technologies | 0.9x | n/a | CA$2.7m |
CFT Craftport Cannabis | 14.2x | n/a | CA$2.7m |
IPCI.H Intellipharmaceutics International | 2.1x | n/a | CA$2.6m |
LOBE Lobe Sciences | 2.6x | n/a | CA$2.6m |
AREV AREV Life Sciences Global | 15.5x | n/a | CA$2.9m |
Price-To-Sales vs Peers: AREV is expensive based on its Price-To-Sales Ratio (15.5x) compared to the peer average (4.8x).
Price to Earnings Ratio vs Industry
How does AREV's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?
Price-To-Sales vs Industry: AREV is expensive based on its Price-To-Sales Ratio (15.5x) compared to the Canadian Pharmaceuticals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is AREV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 15.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate AREV's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.